Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Published Online
on September 21, 2009

Hypertension. 2009
Published online before print September 21, 2009, doi: 10.1161/HYPERTENSIONAHA.109.136655
A more recent version of this article appeared on November 1, 2009
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
54/5/1084    most recent
HYPERTENSIONAHA.109.136655v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Fagard, R. H.
Right arrow Articles by Wouters, S.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fagard, R. H.
Right arrow Articles by Wouters, S.
Right arrowPubmed/NCBI databases
Medline Plus Health Information
*Blood Pressure Medicines
*High Blood Pressure
Related Collections
Right arrow Hypertrophy
Right arrow Clinical Studies
Right arrow Other Treatment

Submitted on May 22, 2009
Revised on June 15, 2009

Regression of Left Ventricular Mass by Antihypertensive Treatment. A Meta-Analysis of Randomized Comparative Studies

Robert H. Fagard*; Hilde Celis; Lutgarde Thijs; and Stijn Wouters

From the Hypertension and Cardiovascular Rehabilitation Unit, Faculty of Medicine, University of Leuven KU Leuven, Leuven, Belgium.

* To whom correspondence should be addressed. E-mail: robert.fagard{at}uz.kuleuven.ac.be.

Abstract—Blood pressure–lowering therapy reduces left ventricular mass, but the question of whether differences exist among drug classes has not been fully resolved. Our aim was to compare the effects of diuretics, {beta}-blockers, calcium channel blockers, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers on left ventricular mass regression in patients with hypertension on the basis of prospective, randomized comparative studies. We performed meta-analyses, involving pooled pairwise comparisons of the drug classes and of each class versus other classes statistically combined, and meta-regression analyses to identify the determinants of the regression. The 75 relevant publications involved 84 pairwise comparisons and 6001 patients. Regression of left ventricular mass was significantly less (P=0.01) with {beta}-blockers (9.8%) than with angiotensin receptor blockers (12.5%), but none of the other analyzable pairwise comparisons between drug classes revealed significant differences (P>0.10). In addition, {beta}-blockers showed less regression than the other 4 classes statistically combined (P<0.01), and regression was more pronounced with angiotensin receptor blockers versus the others (P<0.01). In multivariable meta-regression analysis on all of the treatment arms, {beta}-blocker treatment was a significant and negative predictor of the regression (-3.6%; P<0.01), but this was not the case for the other drug classes, including angiotensin receptor blockers. In conclusion, {beta}-blockers show less regression of left ventricular mass, whereas angiotensin receptor blockers may induce larger regression. The inferiority of {beta}-blockers appears to be more convincing than the superiority of angiotensin receptor blockers.


Key words: angiotensin-converting enzyme inhibitor • angiotensin receptor blocker • {beta}-blocker • calcium channel blocker • diuretic • left ventricular mass • meta-analysis